10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $3.0B | $72M | 36.9% | 13.1% | $270M | $2.6B | $282M |
| 2024 | $2.8B | -$117M | 36.5% | 8.9% | $243M | $2.4B | $111M |
| 2023 | $2.4B | -$84M | 34.3% | 8.5% | $302M | $2.4B | $92M |
| 2022 | $2.2B | -$271M | 35.5% | -4.3% | $19M | $2.6B | $26M |
| 2021 | $2.1B | $13M | 36.7% | 7.3% | $194M | $2.7B | $248M |
| 2020 | $2.0B | $68M | 31.5% | 4.6% | $323M | $2.8B | $341M |
| 2019 | $1.6B | -$604M | 21.7% | -15.3% | -$45M | $2.6B | $151M |
| 2018 | $1.7B | -$20M | 43.1% | -1.2% | $167M | $2.7B | $213M |
| 2017 | $1.0B | $0 | 50.9% | 23.7% | $139M | $1.4B | $74M |
| 2016 | $1.0B | $0 | 58.7% | 28.0% | -$8M | — | $27M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $723M | $62M | 44.3% | 19.6% | -$35M | $2.6B | $198M |
| Dec '25 | $814M | $35M | 36.5% | 13.8% | $109M | $2.6B | $282M |
| Sep '25 | $785M | $2M | 34.9% | 9.0% | $106M | $2.6B | $201M |
| Jun '25 | $725M | $22M | 39.5% | 15.4% | $61M | $2.2B | $72M |
| Mar '25 | $695M | $12M | 36.8% | 14.4% | -$6M | $2.2B | $59M |
| Dec '24 | $731M | -$31M | 36.0% | 10.4% | $103M | $2.4B | $111M |
| Sep '24 | $702M | -$156000 | 38.4% | 12.6% | $125M | $2.4B | $74M |
| Jun '24 | $702M | $6M | 35.6% | 13.6% | $29M | $2.4B | $44M |
| Mar '24 | $659M | -$92M | 36.1% | -1.6% | -$14M | $2.4B | $47M |
| Dec '23 | $617M | -$101M | 30.8% | 2.3% | $126M | $2.4B | $92M |
| Sep '23 | $620M | $10M | 37.5% | 12.2% | $70M | $2.6B | $87M |
| Jun '23 | $599M | $12M | 36.7% | 13.4% | -$23M | $2.6B | $109M |
| Mar '23 | $558M | -$7M | 32.0% | 6.2% | $130M | $2.6B | $145M |
| Dec '22 | $610M | -$12M | 35.3% | 5.9% | -$35M | $2.6B | $26M |
| Sep '22 | $546M | -$8M | 35.6% | 8.1% | $74M | $2.6B | $87M |
| Jun '22 | $559M | -$242M | 35.8% | -35.5% | -$131M | $2.7B | $92M |
| Mar '22 | $498M | -$9M | 35.1% | 4.7% | $110M | $2.7B | $210M |
| Dec '21 | $537M | -$22M | 31.0% | 2.1% | $46M | $2.7B | $248M |
| Sep '21 | $529M | -$8M | 37.6% | 5.4% | $72M | $2.7B | $303M |
| Jun '21 | $535M | $30M | 39.7% | 12.5% | -$60M | $2.8B | $278M |
How the market has priced AMRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Amneal Pharmaceuticals, Inc.'s revenue has grown 8.7% per year, and net income grown 1.2% per year. These are computed facts, not advice.
As of FY2025, Amneal Pharmaceuticals, Inc. reported $2.6B of total debt against $282M of cash.
In FY2025, gross margin was 36.9%, operating margin 13.1%, and net margin 2.4%.
As of Jun '26, Amneal Pharmaceuticals, Inc. traded at a price-to-earnings ratio of about 76.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.